- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03181880
To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease (ASTUTE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patient is aged 40 years or older;
- Confirmed diagnosis of COPD;
- Spirometry performed at study entry or within the last 3 months preceding study entry with a post-bronchodilator Forced Expiratory Volume in 1 Second/Forced Vital Capacity quotient less than 0.7;
- Patient is a current smoker or an ex-smoker with a smoking history of ≥10 pack-years;
Patient belongs to any of these treatment groups:
- Patient is treated by a monotherapy long-acting bronchodilator (Long-Acting Muscarinic Antagonist or Long-Acting Beta Agonist), or
- Naïve COPD patient, defined as:
- Patient is newly diagnosed, or
- Patient is naïve to maintenance therapy, or
- Patient is treated with short acting bronchodilators as rescue medication, or
- Patient has not been treated with long acting bronchodilators in the last 3 months.
Exclusion Criteria:
-
Patients should not be included in the study if any of the following exclusion criteria applies:
- Patient changed COPD treatment regimen over the preceding 3 months;
- Patient treated or intended to be treated at the time of randomisation with a maintenance regimen of inhaled corticosteroids or inhaled corticosteroids-containing medications;
- Patient treated or intended to be treated at the time of randomisation with aclidinium bromide/formoterol fumarate dihydrate inhalation powder;
- Patient had a previous diagnosis of asthma or is suspected of having asthma, asthma-COPD overlap or any other chronic respiratory disease other than COPD (including severe ones, such as cystic fibrosis, pulmonary fibrosis, active neoplasm except adequately treated [no evidence of recurrence within 5 years], active tuberculosis);
- Patient developed a respiratory tract infection or COPD exacerbation within 6 weeks (or 3 months if an exacerbation-related hospitalisation was required) before the randomisation visit;
- Patient with a history of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines, lactose monohydrate, inhaled medication, or any component thereof (including report of paradoxical bronchospasm);
- Patient has been previously enrolled in the current study.
- Any condition that in the Investigator's opinion, would limit a patient's ability to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Aclidinium/formoterol
Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
|
Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators. The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®). Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment.
Other Names:
|
ACTIVE_COMPARATOR: Bronchodilators
The comparator arm consists of SOC.
|
Brochodilators
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in overall early morning COPD symptom severity score of aclidinium bromide/formoterol fumarate dihydrate inhalation powder vs. Standard of Care bronchodilators as measured by the Early Morning Symptoms of COPD Instrument over 12 wks.
Time Frame: study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84
|
Changes from baseline compared between aclidinium bromide/formoterol fumarate dihydrate inhalation powder and Standard of Care bronchodilators.
Baseline values for EMSCI will be averaged over the study entry and previous day.
For longitudinal analyses, each daily measure will be aggregated on a weekly (7 days) basis during the weeks of measurement (weeks 4, 8, and/or 12) by taking the mean value of all available measurements during the week.
|
study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84
|
Change from baseline in overall night time COPD symptom severity score of aclidinium bromide/formoterol fumarate dihydrate inhalation powder vs. Standard of Care bronchodilators as measured by the Nighttime Symptoms of COPD Instrument over 12 weeks.
Time Frame: study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84
|
Changes from baseline compared between aclidinium bromide/formoterol fumarate dihydrate inhalation powder and Standard of Care bronchodilators.
Baseline values for NiSCI will be averaged over the study entry and previous day.
For longitudinal analyses, each daily measure will be aggregated on a weekly (7 days) basis during the weeks of measurement (weeks 4, 8, and/or 12) by taking the mean value of all available measurements during the week.
|
study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in daily RS total Score of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the E-RS™COPD scale over 12 weeks.
Time Frame: study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84
|
Baseline values of the RS-Total Score will be collected and averaged at the study entry visit and previous day. The secondary effectiveness variable will be estimated by the change from baseline in daily RS-Total Score over 12 weeks of treatment. |
study entry and previous day (retrospectively), days 22-28, days 50-56, days 78-84
|
Change from baseline in health status of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilatorsmeasured by the COPD assessment Test (CAT) over 12 weeks.
Time Frame: study entry, days 28, 56 and 84
|
The CAT measures the health status of patients with COPD.
If the response to 1 of the 8 items is missing, the score will be considered missing.
Change from baseline in health status over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12) will be calculated.
These change scores will be the CAT endpoint.
|
study entry, days 28, 56 and 84
|
Change from baseline in total time index of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the Yale Physical Activity Survey (YPAS) over 12 weeks.
Time Frame: study entry, days 28, 56 and 84
|
The Total Time Index will be calculated at baseline and over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12).
Change from baseline will be calculated.
These change scores will be the Total Time Index analysed.
|
study entry, days 28, 56 and 84
|
Change from baseline in Energy Expenditure Index of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the Yale Physical Activity Survey (YPAS) over 12 weeks.
Time Frame: study entry, days 28, 56 and 84
|
The Energy Expenditure Index will be calculated at baseline and over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12).
Change from baseline will be calculated.
These change scores will be the Energy Expenditure Index analysed.
|
study entry, days 28, 56 and 84
|
Change from baseline in Activity Dimensions Summary Index of aclidinium bromide/formoterol fumarate dihydrate inhalation powder versus Standard of Care bronchodilators measured by the Yale Physical Activity Survey (YPAS) over 12 weeks.
Time Frame: study entry, days 28, 56 and 84
|
The Activity Dimensions Summary Index will be calculated at baseline and over 12 weeks of follow-up (on the last day of weeks 4, 8, and 12).
Change from baseline will be calculated.
These change scores will be the Activity Dimensions Summary Index analysed.
|
study entry, days 28, 56 and 84
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Anna Ribera, AstraZeneca
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Anticonvulsants
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Bromides
- Formoterol Fumarate
Other Study ID Numbers
- D6570R00004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Aclidinium bromide/formoterol fumarate combination
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Australia, Canada, New Zealand
-
AstraZenecaParexelCompletedCOPDPhilippines, Vietnam, China, Taiwan, India
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Australia, Canada, New Zealand
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Russian Federation, Australia, Czech Republic, Poland
-
University of DundeeAstraZeneca; NHS TaysideCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Canada
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium, Germany
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine